메뉴 건너뛰기
Canadian Journal of Psychiatry
Volumn 48, Issue 5, 2003, Pages 353-354
Treatment noncompliance with orally disintegrating olanzapine tablets [9]

(1)  Freudenreich, Oliver a  

a NONE
Author keywords

[No Author keywords available]
Indexed keywords

HALOPERIDOL DECANOATE; OLANZAPINE;
EID: 0037932665     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370304800521     Document Type: Letter
Times cited : (8)
References (3)
  • 1
    • 0036810029 scopus 로고    scopus 로고
    • Dissolution profile, tolerability, and acceptability of the orally disintegrating olanzapine tablet in patients with schizophrenia
    • Chue P, Jones B, Taylor CC, Dickson R. Dissolution profile, tolerability, and acceptability of the orally disintegrating olanzapine tablet in patients with schizophrenia. Can J Psychiatry 2002;47:771-4.
    • (2002) Can J Psychiatry , vol.47 , pp. 771-774
    • Chue, P.1    Jones, B.2    Taylor, C.C.3    Dickson, R.4
  • 2
    • 0031958859 scopus 로고    scopus 로고
    • Drug-delivery products and the Zydis fast-dissolving dosage form
    • Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol 1998;50:375-82.
    • (1998) J Pharm Pharmacol , vol.50 , pp. 375-382
    • Seager, H.1
  • 3
    • 0030698640 scopus 로고    scopus 로고
    • Determinants of medication compliance in schizophrenia: Empirical and clinical findings
    • Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637-51.
    • (1997) Schizophr Bull , vol.23 , pp. 637-651
    • Fenton, W.S.1    Blyler, C.R.2    Heinssen, R.K.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.